IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Beskrivelse
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
Prøv gratis i 14 dager
99 kr / Måned etter prøveperioden. · Avslutt når som helst
- Eksklusive podkaster
- 20 timer lydbøker i måneden
- Gratis podkaster
Kommentarer
0Vær den første til å kommentere
Registrer deg nå og bli medlem av IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option sitt community!